Minnema M, Nasserinejad K, Hazenberg B, et al. HOVON 104: results from a multicenter, prospective phase II study of bortezomib based induction treatment followed by autoogous stem cell transplantation in patients with de novo AL amyloidosis. EHA 2017, abstract S411.
Roxadustat opgenomen in Geneesmiddelenvergoedingssysteem
sep 2021 | Benigne hematologie, Chronische nierschade